186 related articles for article (PubMed ID: 1560343)
1. A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: in vitro studies.
Reiter Z; Ozés ON; Blatt LM; Sturzl M; Taylor MW
J Acquir Immune Defic Syndr (1988); 1992; 5(5):469-76. PubMed ID: 1560343
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acquired immunodeficiency syndrome--related Kaposi's sarcoma with lymphoblastoid interferon.
Rios A; Mansell PW; Newell GR; Reuben JM; Hersh EM; Gutterman JU
J Clin Oncol; 1985 Apr; 3(4):506-12. PubMed ID: 3872349
[TBL] [Abstract][Full Text] [Related]
3. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.
Reiter Z; Ozes ON; Blatt LM; Taylor MW
Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 1):103-11. PubMed ID: 1370257
[TBL] [Abstract][Full Text] [Related]
4. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
5. Viral infections and cell-mediated immunity in immunodeficient homosexual men with Kaposi's sarcoma treated with human lymphoblastoid interferon.
Frederick WR; Epstein JS; Gelmann EP; Rook AH; Armstrong GR; Djeu JY; Jackson L; Manischewitz JF; Enterline J; Jacob J
J Infect Dis; 1985 Jul; 152(1):162-70. PubMed ID: 2989380
[TBL] [Abstract][Full Text] [Related]
6. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome.
Vadhan-Raj S; Wong G; Gnecco C; Cunningham-Rundles S; Krim M; Real FX; Oettgen HF; Krown SE
Cancer Res; 1986 Jan; 46(1):417-25. PubMed ID: 2415251
[TBL] [Abstract][Full Text] [Related]
7. Recognition of heterogeneous lymphokine-activated killer (LAK) receptors on Kaposi's sarcoma cells, endothelial cells, and monocytes/macrophages: evidence of distinct LAK-cell antigen on Kaposi's sarcoma cells--potential for use of LAK cells for immunotherapy.
Rahman MU; Mazumder A
J Clin Immunol; 1992 Jul; 12(4):281-8. PubMed ID: 1355096
[TBL] [Abstract][Full Text] [Related]
8. Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation.
Reiter Z; Tomson S; Ozes ON; Taylor MW
Blood; 1993 Apr; 81(7):1699-708. PubMed ID: 8096405
[TBL] [Abstract][Full Text] [Related]
9. Recombinant leukocyte A interferon in Kaposi's sarcoma.
Krown SE; Real FX; Krim M; Cunningham-Rundles S; Koziner B; Myskowski PL; Safai B; Oettgen HF
Ann N Y Acad Sci; 1984; 437():431-8. PubMed ID: 6398651
[No Abstract] [Full Text] [Related]
10. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma.
Krown SE; Real FX; Cunningham-Rundles S; Myskowski PL; Koziner B; Fein S; Mittelman A; Oettgen HF; Safai B
N Engl J Med; 1983 May; 308(18):1071-6. PubMed ID: 6835320
[No Abstract] [Full Text] [Related]
11. Killing of Kaposi's sarcoma-associated herpesvirus-infected fibroblasts during latent infection by activated natural killer cells.
Matthews NC; Goodier MR; Robey RC; Bower M; Gotch FM
Eur J Immunol; 2011 Jul; 41(7):1958-68. PubMed ID: 21509779
[TBL] [Abstract][Full Text] [Related]
12. Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells.
Murakami-Mori K; Mori S; Bonavida B; Nakamura S
J Immunol; 1999 Mar; 162(6):3672-9. PubMed ID: 10092829
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
14. NKG2C+ NK cells are enriched in AIDS patients with advanced-stage Kaposi's sarcoma.
Goodier MR; Mela CM; Steel A; Gazzard B; Bower M; Gotch F
J Virol; 2007 Jan; 81(1):430-3. PubMed ID: 17035308
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 concentrations in the serum of patients with AIDS-associated Kaposi's sarcoma during treatment with interferon-alpha.
de Wit R; Raasveld MH; ten Berge RJ; van der Wouw PA; Bakker PJ; Veenhof CH
J Intern Med; 1991 Jun; 229(6):539-42. PubMed ID: 2045763
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of 5 patients affected by Kaposi's sarcoma and AIDS with recombinant interferon alfa-2A (roferon-A)].
Lopez Bran E; Aguilar R; Marron JA; Figueredo MA; Garcia Ruiz JM
Med Cutan Ibero Lat Am; 1989; 17(4):269-73. PubMed ID: 2693866
[TBL] [Abstract][Full Text] [Related]
17. Induction of lymphokine-activated killer and natural killer cell activities from cryopreserved lymphocytes.
Kawai H; Komiyama A; Katoh M; Yabuhara A; Miyagawa Y; Akabane T
Transfusion; 1988; 28(6):531-5. PubMed ID: 3264091
[TBL] [Abstract][Full Text] [Related]
18. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
[TBL] [Abstract][Full Text] [Related]
19. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).
Lane HC; Davey RT; Sherwin SA; Masur H; Rook AH; Manischewitz JF; Quinnan GV; Smith PD; Easter ME; Fauci AS
J Clin Immunol; 1989 Jul; 9(4):351-61. PubMed ID: 2549086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
